STOCK TITAN

Zynex, Inc. to Postpone Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

ENGLEWOOD, Colo., March 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m. ET.

The company will announce its fourth quarter and full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.

About Zynex, Inc.
Zynex, founded in 1996, develops, manufacturers, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com

Contact: Zynex, Inc. (800) 495-6670

Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
ir@zynex.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-inc-to-postpone-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call-301763794.html

SOURCE Zynex

ZYNEX INC

NASDAQ:ZYXI

ZYXI Rankings

ZYXI Latest News

ZYXI Stock Data

368.47M
15.72M
51.14%
31.25%
18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ENGLEWOOD

About ZYXI

zynex, inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. zynex medical is a provider of electrotherapy products for home use. zynex monitoring solutions develops products for cardiac monitoring for use in hospitals. zynex neurodiagnostics develops devices for emg and eeg diagnostic applications within neurology disciplines. zynex medical's product line is fully developed, fda/ce cleared, commercially sold, and has been developed to uphold the company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. zynex monitoring solutions and zynex neurodiagnostics are currently both in the development stages without any significant revenues.